Publication at Second Faculty of Medicine |
2015
Abstract
Type 2 diabetes mellitus is a heterogeneous disease, with the existing means failing to reach target values of compensation inall patients. Therefore, completely new options for treating hyperglycaemia are beingsought andfound (SGLT2 inhibitors, gliptins, GLP-1 receptor agonists).
These newpharmaceuticals are at least as effective asolder typesof antidiabetic drugs, but they are certainly safer. Theirkey propertyis minimal riskof hypoglycaemia.
They gradually expand the pharmacotherapyoptions for type 2 diabetes andallow for individual selection and adjustmentof treatment. agonists, liraglutide, exenatide, lixisenatide.